Xspray Pharma licenses patent rights to Handa Therapeutics, secures royalty agreement
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Subscribe To Our Newsletter & Stay Updated